Targeting mitochondrial RNA polymerase in acute myeloid leukemia.

Oncotarget (2015-10-21)
Fernando N Bralha, Sanduni U Liyanage, Rose Hurren, Xiaoming Wang, Meong Hi Son, Thomas A Fung, Francine B Chingcuanco, Aveline Y W Tung, Ana C Andreazza, Pamela Psarianos, Aaron D Schimmer, Leonardo Salmena, Rebecca R Laposa
ABSTRACT

Acute myeloid leukemia (AML) cells have high oxidative phosphorylation and mitochondrial mass and low respiratory chain spare reserve capacity. We reasoned that targeting the mitochondrial RNA polymerase (POLRMT), which indirectly controls oxidative phosphorylation, represents a therapeutic strategy for AML. POLRMT-knockdown OCI-AML2 cells exhibited decreased mitochondrial gene expression, decreased levels of assembled complex I, decreased levels of mitochondrially-encoded Cox-II and decreased oxidative phosphorylation. POLRMT-knockdown cells exhibited an increase in complex II of the electron transport chain, a complex comprised entirely of subunits encoded by nuclear genes, and POLRMT-knockdown cells were resistant to a complex II inhibitor theonyltrifluoroacetone. POLRMT-knockdown cells showed a prominent increase in cell death. Treatment of OCI-AML2 cells with 10-50 µM 2-C-methyladenosine (2-CM), a chain terminator of mitochondrial transcription, reduced mitochondrial gene expression and oxidative phosphorylation, and increased cell death in a concentration-dependent manner. Treatment of normal human hematopoietic cells with 2-CM at concentrations of up to 100 µMdid not alter clonogenic growth, suggesting a therapeutic window. In an OCI-AML2 xenograft model, treatment with 2-CM (70 mg/kg, i.p., daily) decreased the volume and mass of tumours to half that of vehicle controls. 2-CM did not cause toxicity to major organs. Overall, our results in a preclinical model contribute to the functional validation of the utility of targeting the mitochondrial RNA polymerase as a therapeutic strategy for AML.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
HEPES, ≥99.5% (titration)
Sigma-Aldrich
HEPES, BioPerformance Certified, ≥99.5% (titration), suitable for cell culture
Sigma-Aldrich
Propidium iodide, ≥94.0% (HPLC)
Sigma-Aldrich
HEPES buffer solution, 1 M in H2O
Sigma-Aldrich
Propidium iodide solution, solution (1.0 mg/ml in water)
SAFC
HEPES
Sigma-Aldrich
HEPES, BioUltra, for molecular biology, ≥99.5% (T)
Sigma-Aldrich
Tetramethylrhodamine methyl ester perchlorate, ≥95%
Sigma-Aldrich
KiCqStart® SYBR® Green qPCR ReadyMix, For Bio-Rad, Cepheid, Eppendorf, Illumina, Corbett, and Roche systems
SAFC
HEPES
Sigma-Aldrich
HEPES, BioXtra, pH 5.0-6.5 (1 M in H2O), ≥99.5% (titration)
Sigma-Aldrich
KiCqStart® SYBR® Green qPCR ReadyMix, Low ROX, for ABI and Stratagene instruments
Sigma-Aldrich
HEPES, BioXtra, suitable for mouse embryo cell culture, ≥99.5% (titration)
Sigma-Aldrich
HEPES, anhydrous, free-flowing, Redi-Dri, ≥99.5%
Sigma-Aldrich
KiCqStart® SYBR® Green qPCR ReadyMix, iQ, with fluorescein for Bio-Rad systems
Sigma-Aldrich
MISSION® esiRNA, targeting human POLRMT
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Polrmt